Login to Your Account

Intercept Pharma to launch pivotal phase III in NASH

By Michael Fitzhugh
Staff Writer

Tuesday, May 19, 2015

Following extensive talks with the FDA and European regulators, Intercept Pharmaceuticals Inc. has nailed down plans for a rigorous pivotal phase III study testing obeticholic acid, its lead candidate, in about 2,500 patients with NASH.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription